Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

Autor: Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Mariacristina Di Marco, Guido Giordano, Enrico Vasile, Mario Scartozzi, Silvia Bozzarelli, Silvia Noventa, Maria Grazia Rodriquenz, Anna Maria Militello, Ilario Giovanni Rapposelli, Ingrid Garajova, Stefania De Lorenzo, Barbara Merelli, Alessandro Bittoni, Lisa Salvatore, Letizia Procaccio, Chiara Paratore, Andrea Spallanzani, Umberto Peretti, Monica Niger, Elisa Giommoni, Ilaria Bernardini, Emiliano Tamburini, Katia Bernardino, Laura Forti, Maria Maddalena Valente, Stefano Cascinu, Michele Milella, Michele Reni
Rok vydání: 2022
Předmět:
Zdroj: British Journal of Cancer. 128:877-885
ISSN: 1532-1827
0007-0920
Popis: Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second-line therapy (2LT) outcome in this setting is lacking.Data of gBRCA1-2pv metastatic PDAC patients treated with chemotherapy were collected. A primary analysis of 2LT RECIST response, median progression-free survival (mPFSEighty-four gBRCA1-2pv metastatic PDAC patients were enrolled. The primary analysis, including 43 patients, highlighted a significant improvement of mPFSThis study highlighted the beneficial role of platinum agents in gBRCA1-2pv PDAC patients also in second-line treatment setting. However, our data suggest that early use of 3- and 4-drug platinum-based chemotherapy combinations provides a survival outcome advantage.
Databáze: OpenAIRE
Externí odkaz: